Retrieve available abstracts of 25 articles: HTML format
Single Articles
June 2025
MONSON KR, Ferguson R, Handzlik JE, Morales L, et al Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition
efficacy in melanoma.
Nat Med. 2025 Jun 5. doi: 10.1038/s41591-025-03699. PubMedAbstract available
May 2025
MIGLINO N, Toussaint NC, Ring A, Bonilla X, et al Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
Nat Med. 2025 May 27. doi: 10.1038/s41591-025-03715. PubMedAbstract available
January 2025
DUMMER R, Robert C, Scolyer RA, Taube JM, et al Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic
virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.
Nat Med. 2025 Jan 7. doi: 10.1038/s41591-024-03411. PubMedAbstract available
BORGERS JSW, Lenkala D, Kohler V, Jackson EK, et al Personalized, autologous neoantigen-specific T cell therapy in metastatic
melanoma: a phase 1 trial.
Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03418. PubMedAbstract available
June 2024
LONG GV, Carlino MS, Au-Yeung G, Spillane AJ, et al Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant
resectable melanoma: the randomized phase 2 NeoTrio trial.
Nat Med. 2024 Jun 21. doi: 10.1038/s41591-024-03077. PubMedAbstract available
O'LEARY K Neoadjuvant immunotherapy a new standard of care for melanoma.
Nat Med. 2024 Jun 17. doi: 10.1038/d41591-024-00045. PubMed
February 2024
BJORK JR, Bolte LA, Maltez Thomas A, Lee KA, et al Longitudinal gut microbiome changes in immune checkpoint blockade-treated
advanced melanoma.
Nat Med. 2024 Feb 16. doi: 10.1038/s41591-024-02803. PubMedAbstract available
January 2024
O'LEARY K Personalized mRNA vaccine boosts melanoma immunotherapy.
Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006. PubMed
KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary
results from the randomized, phase 3 CheckMate 76K trial.
Nat Med. 2024 Jan 4. doi: 10.1038/s41591-023-02775. PubMed
November 2023
FRATERMAN I, Reijers ILM, Dimitriadis P, Broeks A, et al Association between pretreatment emotional distress and neoadjuvant immune
checkpoint blockade response in melanoma.
Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02631. PubMedAbstract available
ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy
in advanced melanoma: a phase I trial.
Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02650. PubMed
KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma:
primary results from the randomized, phase 3 CheckMate 76K trial.
Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02661. PubMed
October 2023
KIRKWOOD J, Del Vecchio M, Weber J, Hoeller C, et al Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the
randomized, phase 3 CheckMate 76K trial.
Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02583. PubMedAbstract available
August 2023
VANDERWALDE A, Bellasea SL, Kendra KL, Khushalani NI, et al Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory
metastatic melanoma: a randomized phase 2 trial.
Nat Med. 2023 Aug 17. doi: 10.1038/s41591-023-02498. PubMedAbstract available
CARVALHO T Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in
melanoma trial.
Nat Med. 2023 Aug 16. doi: 10.1038/d41591-023-00072. PubMed
BARATA C, Rotemberg V, Codella NCF, Tschandl P, et al A reinforcement learning model for AI-based decision support in skin cancer.
Nat Med. 2023;29:1941-1946. PubMedAbstract available
July 2023
ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced
melanoma: a phase I trial.
Nat Med. 2023 Jul 6. doi: 10.1038/s41591-023-02453. PubMedAbstract available
BRASTIANOS PK, Kim AE, Giobbie-Hurder A, Lee EQ, et al Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
Nat Med. 2023;29:1728-1737. PubMedAbstract available
May 2023
GARBE C, Dummer R, Amaral T, Amaria RN, et al Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
Nat Med. 2023 May 16. doi: 10.1038/s41591-023-02336. PubMed
April 2023
LIU S, Dharanipragada P, Lomeli SH, Wang Y, et al Multi-organ landscape of therapy-resistant melanoma.
Nat Med. 2023 Apr 27. doi: 10.1038/s41591-023-02304. PubMedAbstract available
GLITZA OLIVA IC, Ferguson SD, Bassett R Jr, Foster AP, et al Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase
1 trial interim results.
Nat Med. 2023;29:898-905. PubMedAbstract available
March 2023
O'LEARY K Earlier appears better for immunotherapy in melanoma.
Nat Med. 2023 Mar 16. doi: 10.1038/d41591-023-00028. PubMed
CASCONE T, Leung CH, Weissferdt A, Pataer A, et al Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable
non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
Nat Med. 2023 Mar 16. doi: 10.1038/s41591-022-02189. PubMedAbstract available
February 2023
TIAN J, Chen JH, Chao SX, Pelka K, et al Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase
2 trial.
Nat Med. 2023;29:458-466. PubMedAbstract available
NIKNAFS N, Balan A, Cherry C, Hummelink K, et al Persistent mutation burden drives sustained anti-tumor immune responses.
Nat Med. 2023;29:440-449. PubMedAbstract available